Critical Path Institute (C-Path) is thrilled to announce its Polycystic Kidney Disease Outcomes Consortium (PKDOC) has been awarded an Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) focused Broad Agency Announcement (BAA) contract from the U.S. Food and Drug Administration (FDA).
The overarching objective of the work supported by the BAA award is to leverage collaboration with the Wake Forest Rare Inherited Kidney Disease team and its ADTKD registry, to analyze clinical and laboratory data that will help evaluate prognosis in ADTKD and help set the stage for future clinical trials. ADTKD only affects the kidney, resulting in slowly worsening kidney function and the need for dialysis or kidney transplant at an average age of 45 years. It is caused predominantly by genetic changes (mutations) in the UMOD and MUC1 genes.
Because of the inheritance pattern (autosomal dominant), a child of an affected parent has a 50% chance of also being affected. Thus, many family members have kidney disease and will eventually need a kidney transplant or dialysis. Unlike many other kidney diseases, there is no blood or protein in the urine.
While this condition was infrequently recognized in the past, identification of the genetic causes of this condition has resulted in increased detection. It is now estimated that ADTKD is the third most common form of inherited kidney disease and affects more than 25,000 individuals in the U.S.
Given its recent identification as a cause of kidn.